Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption

Bone

Volumn 28, Issue 1, 2001, Pages 54-64

  Violette, S M ^a   Guan, W ^a   Bartlett, C ^a   Smith, J A ^a   Bardelay, C ^b   Antoine, E ^b   Rickles, R J ^a   Mandine, E ^b   Van Schravendijk, M R ^a   Adams, S E ^a   Lynch, B A ^a   Shakespeare, W C ^a   Yang, M ^a   Jacobsen, V A ^a   Takeuchi, C S ^a   Macek, K J ^a   Bohacek, R S ^a   Dalgarno, D C ^a   Weigele, M ^a   Lesuisse, D ^b   Sawyer, T K ^a   Baron, R ^b   more..

^a ARIAD PHARMACEUTICALS INC   (United States)

^b SANOFI   (France)

Author keywords

Bisphosphonate; Osteoclast; Osteoporosis; Resorption; SH2 domain; src

Indexed keywords

AP 21946; AP 22188; AP 22408; AP 22409; CORTACTIN; ENZYME INHIBITOR; PHOSPHOTYROSINE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ALBERS SCHOENBERG DISEASE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DENTIN; FLUORESCENCE POLARIZATION; HUMAN; HUMAN CELL; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; RABBIT;

ACTINS; AMINO ACID SEQUENCE; ANIMALS; BONE RESORPTION; CELL LINE, TRANSFORMED; DENTIN; DIPHOSPHONATES; ENZYME INHIBITORS; FIBROBLASTS; HUMANS; LIGANDS; MAMMALS; MICE; MOLECULAR SEQUENCE DATA; OSTEOCLASTS; OSTEOPOROSIS; RABBITS; RADIOLIGAND ASSAY; RATS; SRC HOMOLOGY DOMAINS; SRC-FAMILY KINASES; TRITIUM; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 0035140098     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(00)00427-0     Document Type: Article

References (58)

1. Variable effects of tyrosine kinase inhibitors on avian osteoclastic activity and reduction of bone loss in ovariectomized rats
2. c-src expression for osteoclasts to form ruffled borders and to resorb bone in mice
3. Resorption of dentine by osteoclasts in vitro
4. Regulation, substrates, and functions of Src
5. Oncogenes and signal transduction
6. Osteopontin activation of c-src in human melanoma cells requires the cytoplasmic domain of the integrin alpha v-subunit
7. c-src to integrin-dependent cytoskeletal complexes in thrombin-stimulated platelets
8. Blockade of osteoclast-mediated bone resorption through occupancy of the integrin receptor; a potential approach to the therapy of osteoporosis
9. PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of alpha(v)beta3 integrin, and phosphorylated by src kinase
10. Bisphosphonates; mechanisms of action and clinical use in osteoporosis-an update
11. Localization and characterization of the src-gene product of rous sarcoma virus
12. Evidence that c-src is involved in the process of osteoclast bone resorption
13. src with triton X-100-resistant cellular structure correlates with morphological transformation
14. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor
15. c-src in association with intracellular membranes
16. Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts
17. c-src to the cytoskeleton during platelet aggregation
18. Role of c-Src in cellular events associated with colony-stimulating factor-1-induced spreading in osteoclasts
19. 14C]citric acid
20. A band of F-actin containing podosomes is involved in bone resorption by osteoclasts
21. Association of the amino-terminal half of c-Src with focal adhesions alters their properties and is regulated by phosphorylation of tyrosine 527
22. c-Src enhances the spreading of src-/- fibroblasts on fibronectin by a kinase-independent mechanism
23. Src family kinases are required for integrin but not PDGFR signal transduction
24. Regulation of c-Src tyrosine kinase activity by the Src SH2 domain
25. Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts
26. A fluorescence polarization based Src-SH2 binding assay
27. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo
28. A possible mechanism of the specific action of bisphosphonates on osteoclasts; Tiludronate preferentially affects polarized osteoclasts having ruffled borders
29. SH2 and SH3 domains; from structure to function
30. Identification of a ten-amino acid proline-rich SH3 binding site
31. Identification of Src, Fyn, Lyn, PI3K and Abl SH2 domain ligands using phage display libraries
32. A novel mechanism-based mammalian cell assay for the identification of SH2-domain-specific protein-protein inhibitors
33. DNA synthesis induced by some but not all growth factors requires Src family protein tyrosine kinases
34. Integrin function in osteoclasts
35. Bisphosphonate action
36. Fibronectin-stimulated signaling from a focal adhesion kinase-c-Src complex; involvement of the Grb2, p130cas, and Nck adaptor proteins
37. Evidence for in vivo phosphorylation of the Grb2 SH2-domain binding site on focal adhesion kinase by src-family protein-tyrosine kinases
38. The many faces of Src; multiple functions of a prototypical tyrosine kinase
39. Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mutant mice
40. Effects of SH2 and SH3 deletions on the functional activities of wild-type and transforming variants of c-Src
41. SH2 domains recognize specific phosphopeptide sequences
42. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice
43. Calcitonin-induced changes in the cytoskeleton are mediated by a signal pathway associated with protein kinase A in osteoclasts
44. c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption
45. P125FAK, in osteoclast resorption
46. Clear zone in osteoclast function; role of podosomes in regulation of bone-resorping activity
47. Cellular functions regulated by Src family kinases
48. Specific and redundant roles of src and fyn in organizing the cytoskeleton
49. The Src family tyrosine kinases are required for platelet-derived growth factor-mediated signal transduction in NIH 3T3 cells
50. A Src selective binding compound inhibits osteoclast mediated resorption
51. Discovery of potent and selective SH2 inhibitors of the tyrosine kinase ZAP-70
52. Bone targeted drugs 1. Identification of heterocycles with hydroxyapatite affinity
53. c-src tyrosine kinase inhibitor, inhibits osteoclast bone resorption in vitro and hypercalcemia in vivo
54. Structural basis for the binding of proline-rich peptides to SH3 domains
55. NMDA channel regulation by channel-associated protein tyrosine kinase Src